The study focused on the characteristics and treatment options for transgender individuals assigned male at birth (AMAB) and assigned female at birth (AFAB) at a specific clinic in Italy from March 2021 to July 2023.
A total of 145 patients were observed, revealing similar ages for AMABs (average 26 years) and AFABs (average 25 years), with a small group identifying as non-binary (average 17 years).
Treatments included various forms of hormonal therapy; results showed no increased risk of serious cardiovascular issues in either group, and highlighted the importance of interdisciplinary collaboration in transgender healthcare.